DONG-A ST CO.,LTD
Financials
Valuation Metrics
DONG-A ST CO.,LTD's Market Cap is ₩3478B. At end of 2025 it was ₩4871B. Ranked #595 of 2,421 in KR market (top 25%), #356 of 781 on KOSPI (top 46%), #62 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 347.77B KRW | KR#595/2,421 Sec#62/231 |
| Revenue | 860.94B KRW | KR#445/2,421 Sec#18/231 |
| Net Income | 5.83B KRW | KR#1,148/2,421 Sec#73/231 |
| Total Assets | 1.35T KRW | KR#398/2,421 Sec#18/231 |
| Net Assets | 674.03B KRW | KR#399/2,421 Sec#26/231 |
| Employees | 1,695 | KR#164/2,421 Sec#9/231 |
| Value | ||
| P/E | 59.70x | KR#1,439/2,421 Sec#94/231 |
| P/B | 0.52x | KR#835/2,421 Sec#38/231 |
| P/S | 0.40x | KR#775/2,421 Sec#28/231 |
| EV/EBITDA | 27.33x | KR#1,153/2,421 Sec#68/231 |
| FCF Yield | 1.62% | KR#1,084/2,421 Sec#74/231 |
| Profitability | ||
| ROE | 0.86% | KR#1,488/2,421 Sec#104/231 |
| ROA | 0.43% | KR#1,490/2,421 Sec#104/231 |
| Op. Margin | 2.94% | KR#1,259/2,421 Sec#90/231 |
| Revenue Growth | 15.38% | KR#674/2,421 Sec#63/231 |
| Financial Health | ||
| Debt Ratio | 100.97% | KR#1,567/2,421 Sec#180/231 |
| Total Debt | 479.96B KRW | KR#311/2,421 Sec#10/231 |
| FCF | 5.64B KRW | KR#875/2,421 Sec#58/231 |
| Cash | 136.12B KRW | KR#370/2,421 Sec#16/231 |
| Current Ratio | 1.36x | KR#1,313/2,421 Sec#137/231 |
| Net Debt/EBITDA | 13.59x | KR#1,307/2,421 Sec#92/231 |
| Dividend | ||
| Div. Yield | 1.88% | KR#905/2,421 Sec#46/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -20.58% | KR#1,279/2,421 Sec#88/231 |
| 1M Return | -2.72% | KR#1,557/2,421 Sec#124/231 |
| From 52W High | -36.68% | KR#785/2,421 Sec#51/231 |
| 1Y MDD | -41.95% | KR#656/2,421 Sec#48/231 |
| Trading | ||
| Volume | 1,758 shares | KR#2,283/2,421 Sec#215/231 |
| Trading Value | 63.0M KRW | KR#1,756/2,421 Sec#178/231 |
| Foreign Own. | 19.22% | KR#240/2,421 Sec#12/231 |
| Per Share | ||
| EPS | 599 KRW | KR#930/2,421 Sec#65/231 |
| BPS | 69,288 KRW | KR#196/2,421 Sec#13/231 |
Company Info
Dong-A ST was established in 2013 as a spin-off from Dong-A Socio Holdings and acquired a global ADC specialist in 2023 to secure technology and pipelines. The company manufactures and sells developed new drugs such as STILLEN, Zydena, and Motilitone, along with specialized pharmaceuticals like Growtropin and Gaster, produced at its Cheonan, Daegu, and Songdo campuses. Dong-A ST is expanding R&D investment to develop new drugs for metabolic diseases including diabetes, obesity, and MASH, thereby strengthening its market dominance with a diverse portfolio. Dong-A ST is headquartered in Dongdaemun-gu, Seoul.